Pharmacokinetic Evaluation of New Drugs Using a Multi-Labelling Approach and PET Imaging: Application to a Drug Candidate with Potential Application in Neuromuscular Disorders

Background and objective: The determination of pharmacokinetic properties of new chemical entities is a key step in the process of drug development. Positron emission tomography (PET) is an ideal technique to obtain both biodistribution and pharmacokinetic parameters of new compounds over a wide range of chemical modalities. Here, we use a multi-radionuclide/multi-position labelling approach to investigate distribution, elimination, and metabolism of a triazole-based FKBP12 ligand (AHK2) with potential application in neuromuscular disorders. Methods: Target engagement and stabilizing capacity of the drug candidate (AHK2) towards FKBP12-RyR was evaluated using competitive ligand binding and proximity ligation assays, respectively. Subsequently, AHK2 was labelled either with the positron emitter carbon-11 (11C) via 11C-methylation to yield both [11C]AHK2.1 and [11C]AHK2.2, or by palladium-catalysed reduction of the corresponding 5-iodotriazole derivative using 3H gas to yield [3H]AHK2. Metabolism was first investigated in vitro using liver microsomes. PET imaging studies in rats after intravenous (IV) administration at different doses (1 µg/Kg and 5 mg/Kg) were combined with determination of arterial blood time-activity curves (TACs) and analysis of plasma samples by high performance liquid chromatography (HPLC) to quantify radioactive metabolites. Arterial TACs were obtained in continuous mode by using an in-house developed system that enables extracorporeal blood circulation and continuous measurement of radioactivity in the blood. Pharmacokinetic parameters were determined by non-compartmental modelling of the TACs. Results: In vitro studies indicate that AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. [11C]AHK2.1, [11C]AHK2.2 and [3H]AHK2 could be obtained in overall non-decay corrected radiochemical yields of 14 ± 2%, 15 ± 2% and 0.05%, respectively. Molar activities were 60–110 GBq/µmol, 68–122 GBq/µmol and 0.4–0.5 GBq/μmol, respectively. In vitro results showed that oxidation of the thioether group into sulfoxide, demethylation of the CH3O-Ar residue and demethylation of –N(CH3)2 were the main metabolic pathways. Fast metabolism was observed in vivo. Pharmacokinetic parameters obtained from metabolite-corrected arterial blood TACs showed a short half-life (12.6 ± 3.3 min). Dynamic PET imaging showed elimination via urine when [11C]AHK2.2 was administered, probably reflecting the biodistribution of [11C]methanol as the major metabolite. Contrarily, accumulation in the gastrointestinal track was observed after administration of [11C]AKH2.1. Conclusions: AHK2 binds to FKBP12 at the rapamycin-binding pocket, presenting activity as a FKBP12/RyR stabilizer. Studies performed with the 3H- and 11C-labelled FKBP12/RyR stabilizer AHK2 confirm fast blood clearance, linear pharmacokinetics and rapid metabolism involving oxidation of the sulfide and amine moieties and oxidative demethylation of the CH3-O-Ar and tertiary amine groups as the main pathways. PET studies suggest that knowledge about metabolic pathways is paramount to interpret images.

[1]  P. Gerk,et al.  The Caco-2 Model: Modifications and Enhancements to Improve Efficiency and Predictive Performance. , 2022, International journal of pharmaceutics.

[2]  Oluwole B. Akawa,et al.  Simulation Models for Prediction of Bioavailability of Medicinal Drugs—the Interface Between Experiment and Computation , 2022, AAPS PharmSciTech.

[3]  Chander S Digwal,et al.  PET Molecular Imaging in Drug Development: The Imaging and Chemistry Perspective , 2022, Frontiers in Medicine.

[4]  H. Neumann,et al.  Recent Developments for the Deuterium and Tritium Labeling of Organic Molecules. , 2022, Chemical reviews.

[5]  Vishal B. Siramshetty,et al.  Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability. , 2022, Bioorganic & medicinal chemistry.

[6]  A. López de Munain,et al.  Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress. , 2021, European journal of medicinal chemistry.

[7]  Andreas Wree,et al.  Continuous Blood Sampling in Small Animal Positron Emission Tomography/Computed Tomography Enables the Measurement of the Arterial Input Function. , 2019, Journal of visualized experiments : JoVE.

[8]  F. Hausch,et al.  FKBP Ligands—Where We Are and Where to Go? , 2018, Front. Pharmacol..

[9]  K. Meilleur,et al.  Ryanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches , 2018, Neurotherapeutics.

[10]  L. Nics,et al.  An Overview of PET Radiochemistry, Part 1: The Covalent Labels 18F, 11C, and 13N , 2018, The Journal of Nuclear Medicine.

[11]  N. Srinivas,et al.  Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer. , 2018, Biomedical chromatography : BMC.

[12]  M. Iino,et al.  Genotype–Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel , 2016, Human mutation.

[13]  J. Lanciego,et al.  Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels , 2016, Journal of neurochemistry.

[14]  Karen M. Alsante,et al.  In silico prediction of pharmaceutical degradation pathways: a benchmarking study. , 2014, Molecular pharmaceutics.

[15]  J. Llop,et al.  Nitrogen-13: historical review and future perspectives. , 2014, Journal of labelled compounds & radiopharmaceuticals.

[16]  Jordi Llop,et al.  Assessing Lung Inflammation After Nanoparticle Inhalation Using 2-deoxy-2-[18F]fluoro-d-glucose Positron Emission Tomography Imaging , 2014, Molecular Imaging and Biology.

[17]  J. Llop,et al.  PET Imaging of Serotoninergic Neurotransmission with [11C]DASB and [18F]altanserin after Focal Cerebral Ischemia in Rats , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  Paolo Zanotti-Fregonara,et al.  Kinetic analysis of [11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A , 2013, EJNMMI Research.

[19]  J. Llop,et al.  On 11C Chemistry Reviews - Surveying and Filling the Gaps , 2013 .

[20]  Chuang Lu,et al.  Preclinical experimental models of drug metabolism and disposition in drug discovery and development , 2012 .

[21]  J. Llop,et al.  Facile and improved synthesis of [11C]Me‐QNB , 2012 .

[22]  J. Llop,et al.  Biodistribution and metabolism of 11C-labeled Kendine 91 in mice and rats. , 2012, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[23]  J. Llop,et al.  Fully automated and reproducible radiosynthesis of high specific activity [11C]raclopride and [11C]Pittsburgh compound-B using the combination of two commercial synthesizers , 2011, Nuclear medicine communications.

[24]  T. Shiomi,et al.  Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. , 2011, Cell metabolism.

[25]  Yong Zhang,et al.  PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..

[26]  S. Matecki,et al.  Hypernitrosylated ryanodine receptor/calcium release channels are leaky in dystrophic muscle , 2009, Nature Medicine.

[27]  L. Bass,et al.  A method to estimate dispersion in sampling catheters and to calculate dispersion-free blood time-activity curves. , 2008, Medical physics.

[28]  L. Jia,et al.  The conduct of drug metabolism studies considered good practice (II): in vitro experiments. , 2007, Current drug metabolism.

[29]  Corey W. Liu,et al.  Characterization of the FKBP.rapamycin.FRB ternary complex. , 2005, Journal of the American Chemical Society.

[30]  A. Stammati,et al.  The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics , 2005, Cell Biology and Toxicology.

[31]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[32]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Kessler,et al.  Analysis of emission tomographic scan data: limitations imposed by resolution and background. , 1984, Journal of computer assisted tomography.

[34]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.